Medical Care

Global Anti-VEGF Therapies Market Research Report 2026

This report delivers a comprehensive overview of the global Anti-VEGF Therapies market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-VEGF Therapies. The Anti-VEGF Therapies market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Anti-VEGF Therapies market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Anti-VEGF Therapies manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology
Chengdu Kanghong Pharmaceutical
Segment by Type
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other
Segment by Application
Hospitals
Clinics
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Anti-VEGF Therapies companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-VEGF Therapies Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Bevacizumab
1.2.3 Ramucirumab
1.2.4 Ranibizumab
1.2.5 Aflibercept
1.2.6 Conbercept
1.2.7 Other
1.3 Market by Application
1.3.1 Global Anti-VEGF Therapies Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospitals
1.3.3 Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-VEGF Therapies Market Perspective (2021–2032)
2.2 Global Anti-VEGF Therapies Growth Trends by Region
2.2.1 Global Anti-VEGF Therapies Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Anti-VEGF Therapies Historic Market Size by Region (2021–2026)
2.2.3 Anti-VEGF Therapies Forecasted Market Size by Region (2027–2032)
2.3 Anti-VEGF Therapies Market Dynamics
2.3.1 Anti-VEGF Therapies Industry Trends
2.3.2 Anti-VEGF Therapies Market Drivers
2.3.3 Anti-VEGF Therapies Market Challenges
2.3.4 Anti-VEGF Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-VEGF Therapies Players by Revenue
3.1.1 Global Top Anti-VEGF Therapies Players by Revenue (2021–2026)
3.1.2 Global Anti-VEGF Therapies Revenue Market Share by Players (2021–2026)
3.2 Global Top Anti-VEGF Therapies Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Anti-VEGF Therapies Revenue
3.4 Global Anti-VEGF Therapies Market Concentration Ratio
3.4.1 Global Anti-VEGF Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-VEGF Therapies Revenue in 2025
3.5 Global Key Players of Anti-VEGF Therapies Head Offices and Areas Served
3.6 Global Key Players of Anti-VEGF Therapies, Products and Applications
3.7 Global Key Players of Anti-VEGF Therapies, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Anti-VEGF Therapies Breakdown Data by Type
4.1 Global Anti-VEGF Therapies Historic Market Size by Type (2021–2026)
4.2 Global Anti-VEGF Therapies Forecasted Market Size by Type (2027–2032)
5 Anti-VEGF Therapies Breakdown Data by Application
5.1 Global Anti-VEGF Therapies Historic Market Size by Application (2021–2026)
5.2 Global Anti-VEGF Therapies Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Anti-VEGF Therapies Market Size (2021–2032)
6.2 North America Anti-VEGF Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Anti-VEGF Therapies Market Size by Country (2021–2026)
6.4 North America Anti-VEGF Therapies Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-VEGF Therapies Market Size (2021–2032)
7.2 Europe Anti-VEGF Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Anti-VEGF Therapies Market Size by Country (2021–2026)
7.4 Europe Anti-VEGF Therapies Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Anti-VEGF Therapies Market Size (2021–2032)
8.2 Asia-Pacific Anti-VEGF Therapies Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Anti-VEGF Therapies Market Size by Region (2021–2026)
8.4 Asia-Pacific Anti-VEGF Therapies Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Anti-VEGF Therapies Market Size (2021–2032)
9.2 Latin America Anti-VEGF Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Anti-VEGF Therapies Market Size by Country (2021–2026)
9.4 Latin America Anti-VEGF Therapies Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-VEGF Therapies Market Size (2021–2032)
10.2 Middle East & Africa Anti-VEGF Therapies Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Anti-VEGF Therapies Market Size by Country (2021–2026)
10.4 Middle East & Africa Anti-VEGF Therapies Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Anti-VEGF Therapies Introduction
11.1.4 Roche Revenue in Anti-VEGF Therapies Business (2021–2026)
11.1.5 Roche Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Anti-VEGF Therapies Introduction
11.2.4 Eli Lilly Revenue in Anti-VEGF Therapies Business (2021–2026)
11.2.5 Eli Lilly Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Anti-VEGF Therapies Introduction
11.3.4 Pfizer Revenue in Anti-VEGF Therapies Business (2021–2026)
11.3.5 Pfizer Recent Development
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Company Details
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals Anti-VEGF Therapies Introduction
11.4.4 Regeneron Pharmaceuticals Revenue in Anti-VEGF Therapies Business (2021–2026)
11.4.5 Regeneron Pharmaceuticals Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Anti-VEGF Therapies Introduction
11.5.4 Novartis Revenue in Anti-VEGF Therapies Business (2021–2026)
11.5.5 Novartis Recent Development
11.6 Alphamab Oncology
11.6.1 Alphamab Oncology Company Details
11.6.2 Alphamab Oncology Business Overview
11.6.3 Alphamab Oncology Anti-VEGF Therapies Introduction
11.6.4 Alphamab Oncology Revenue in Anti-VEGF Therapies Business (2021–2026)
11.6.5 Alphamab Oncology Recent Development
11.7 Chengdu Kanghong Pharmaceutical
11.7.1 Chengdu Kanghong Pharmaceutical Company Details
11.7.2 Chengdu Kanghong Pharmaceutical Business Overview
11.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Introduction
11.7.4 Chengdu Kanghong Pharmaceutical Revenue in Anti-VEGF Therapies Business (2021–2026)
11.7.5 Chengdu Kanghong Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Anti-VEGF Therapies Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Bevacizumab
Table 3. Key Players of Ramucirumab
Table 4. Key Players of Ranibizumab
Table 5. Key Players of Aflibercept
Table 6. Key Players of Conbercept
Table 7. Key Players of Other
Table 8. Global Anti-VEGF Therapies Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Anti-VEGF Therapies Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 10. Global Anti-VEGF Therapies Market Size by Region (US$ Million), 2021–2026
Table 11. Global Anti-VEGF Therapies Market Share by Region (2021–2026)
Table 12. Global Anti-VEGF Therapies Forecasted Market Size by Region (US$ Million), 2027–2032
Table 13. Global Anti-VEGF Therapies Market Share by Region (2027–2032)
Table 14. Anti-VEGF Therapies Market Trends
Table 15. Anti-VEGF Therapies Market Drivers
Table 16. Anti-VEGF Therapies Market Challenges
Table 17. Anti-VEGF Therapies Market Restraints
Table 18. Global Anti-VEGF Therapies Revenue by Players (US$ Million), 2021–2026
Table 19. Global Anti-VEGF Therapies Market Share by Players (2021–2026)
Table 20. Global Top Anti-VEGF Therapies Players by Tier (Tier 1, Tier 2, and Tier 3), based on Anti-VEGF Therapies Revenue, 2025
Table 21. Ranking of Global Top Anti-VEGF Therapies Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Anti-VEGF Therapies Revenue (CR5 and HHI), 2021–2026
Table 23. Global Key Players of Anti-VEGF Therapies, Headquarters and Area Served
Table 24. Global Key Players of Anti-VEGF Therapies, Products and Applications
Table 25. Global Key Players of Anti-VEGF Therapies, Date of General Availability (GA)
Table 26. Mergers and Acquisitions, Expansion Plans
Table 27. Global Anti-VEGF Therapies Market Size by Type (US$ Million), 2021–2026
Table 28. Global Anti-VEGF Therapies Revenue Market Share by Type (2021–2026)
Table 29. Global Anti-VEGF Therapies Forecasted Market Size by Type (US$ Million), 2027–2032
Table 30. Global Anti-VEGF Therapies Revenue Market Share by Type (2027–2032)
Table 31. Global Anti-VEGF Therapies Market Size by Application (US$ Million), 2021–2026
Table 32. Global Anti-VEGF Therapies Revenue Market Share by Application (2021–2026)
Table 33. Global Anti-VEGF Therapies Forecasted Market Size by Application (US$ Million), 2027–2032
Table 34. Global Anti-VEGF Therapies Revenue Market Share by Application (2027–2032)
Table 35. North America Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. North America Anti-VEGF Therapies Market Size by Country (US$ Million), 2021–2026
Table 37. North America Anti-VEGF Therapies Market Size by Country (US$ Million), 2027–2032
Table 38. Europe Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 39. Europe Anti-VEGF Therapies Market Size by Country (US$ Million), 2021–2026
Table 40. Europe Anti-VEGF Therapies Market Size by Country (US$ Million), 2027–2032
Table 41. Asia-Pacific Anti-VEGF Therapies Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 42. Asia-Pacific Anti-VEGF Therapies Market Size by Region (US$ Million), 2021–2026
Table 43. Asia-Pacific Anti-VEGF Therapies Market Size by Region (US$ Million), 2027–2032
Table 44. Latin America Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Latin America Anti-VEGF Therapies Market Size by Country (US$ Million), 2021–2026
Table 46. Latin America Anti-VEGF Therapies Market Size by Country (US$ Million), 2027–2032
Table 47. Middle East & Africa Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 48. Middle East & Africa Anti-VEGF Therapies Market Size by Country (US$ Million), 2021–2026
Table 49. Middle East & Africa Anti-VEGF Therapies Market Size by Country (US$ Million), 2027–2032
Table 50. Roche Company Details
Table 51. Roche Business Overview
Table 52. Roche Anti-VEGF Therapies Product
Table 53. Roche Revenue in Anti-VEGF Therapies Business (US$ Million), 2021–2026
Table 54. Roche Recent Development
Table 55. Eli Lilly Company Details
Table 56. Eli Lilly Business Overview
Table 57. Eli Lilly Anti-VEGF Therapies Product
Table 58. Eli Lilly Revenue in Anti-VEGF Therapies Business (US$ Million), 2021–2026
Table 59. Eli Lilly Recent Development
Table 60. Pfizer Company Details
Table 61. Pfizer Business Overview
Table 62. Pfizer Anti-VEGF Therapies Product
Table 63. Pfizer Revenue in Anti-VEGF Therapies Business (US$ Million), 2021–2026
Table 64. Pfizer Recent Development
Table 65. Regeneron Pharmaceuticals Company Details
Table 66. Regeneron Pharmaceuticals Business Overview
Table 67. Regeneron Pharmaceuticals Anti-VEGF Therapies Product
Table 68. Regeneron Pharmaceuticals Revenue in Anti-VEGF Therapies Business (US$ Million), 2021–2026
Table 69. Regeneron Pharmaceuticals Recent Development
Table 70. Novartis Company Details
Table 71. Novartis Business Overview
Table 72. Novartis Anti-VEGF Therapies Product
Table 73. Novartis Revenue in Anti-VEGF Therapies Business (US$ Million), 2021–2026
Table 74. Novartis Recent Development
Table 75. Alphamab Oncology Company Details
Table 76. Alphamab Oncology Business Overview
Table 77. Alphamab Oncology Anti-VEGF Therapies Product
Table 78. Alphamab Oncology Revenue in Anti-VEGF Therapies Business (US$ Million), 2021–2026
Table 79. Alphamab Oncology Recent Development
Table 80. Chengdu Kanghong Pharmaceutical Company Details
Table 81. Chengdu Kanghong Pharmaceutical Business Overview
Table 82. Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Product
Table 83. Chengdu Kanghong Pharmaceutical Revenue in Anti-VEGF Therapies Business (US$ Million), 2021–2026
Table 84. Chengdu Kanghong Pharmaceutical Recent Development
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Authors List of This Report


List of Figures
Figure 1. Anti-VEGF Therapies Picture
Figure 2. Global Anti-VEGF Therapies Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Anti-VEGF Therapies Market Share by Type: 2025 vs 2032
Figure 4. Bevacizumab Features
Figure 5. Ramucirumab Features
Figure 6. Ranibizumab Features
Figure 7. Aflibercept Features
Figure 8. Conbercept Features
Figure 9. Other Features
Figure 10. Global Anti-VEGF Therapies Market Size by Application (US$ Million), 2021–2032
Figure 11. Global Anti-VEGF Therapies Market Share by Application: 2025 vs 2032
Figure 12. Hospitals Case Studies
Figure 13. Clinics Case Studies
Figure 14. Anti-VEGF Therapies Report Years Considered
Figure 15. Global Anti-VEGF Therapies Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Anti-VEGF Therapies Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Anti-VEGF Therapies Market Share by Region: 2025 vs 2032
Figure 18. Global Anti-VEGF Therapies Market Share by Players in 2025
Figure 19. Global Anti-VEGF Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Anti-VEGF Therapies Revenue in 2025
Figure 21. North America Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Anti-VEGF Therapies Market Share by Country (2021–2032)
Figure 23. United States Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Anti-VEGF Therapies Market Share by Country (2021–2032)
Figure 27. Germany Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Anti-VEGF Therapies Market Share by Region (2021–2032)
Figure 35. China Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Anti-VEGF Therapies Market Share by Country (2021–2032)
Figure 43. Mexico Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Anti-VEGF Therapies Market Share by Country (2021–2032)
Figure 47. Israel Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Anti-VEGF Therapies Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Roche Revenue Growth Rate in Anti-VEGF Therapies Business (2021–2026)
Figure 51. Eli Lilly Revenue Growth Rate in Anti-VEGF Therapies Business (2021–2026)
Figure 52. Pfizer Revenue Growth Rate in Anti-VEGF Therapies Business (2021–2026)
Figure 53. Regeneron Pharmaceuticals Revenue Growth Rate in Anti-VEGF Therapies Business (2021–2026)
Figure 54. Novartis Revenue Growth Rate in Anti-VEGF Therapies Business (2021–2026)
Figure 55. Alphamab Oncology Revenue Growth Rate in Anti-VEGF Therapies Business (2021–2026)
Figure 56. Chengdu Kanghong Pharmaceutical Revenue Growth Rate in Anti-VEGF Therapies Business (2021–2026)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies